Effect of Pravastatin, a Potent 3‐Hydroxy‐3‐methylgliitaryl‐coenzyme A Reductase Inhibitor, on Survival of AH130 Hepatoma‐bearing Rats

Open Access
Publisher Website
Google Scholar
Abstract
3‐Hydroxy‐3‐methylglutaryl‐coenzyme A (HMG‐CoA) reductase inhibitor is known to have an inhibitory effect on cell growth in addition to a cholesterol‐lowering effect. This study examined the effect of pravastatin, a potent inhibitor of HMG‐CoA reductase, on the survival of AH130 hepatoma‐bearing rats. Pravastatin (1, 2, or 8 mg/kg body weight) was intraperitoneally injected once a day into tumor‐bearing rats. The difference in the survival curves was significant between the controls and the rats treated with S mg/kg of pravastatin (P < 0.019 by logrank test) but not between the controls and the rats treated with 1 or 2 mg/kg of the inhibitor. The tumor volume was significantly decreased in the rats treated with 8 mg/kg of pravastatin (P < 0.05). These observations showed that intraperitoneal injection of pravastatin could improve the survival of AH130 hepatoma‐bearing rats and had an inhibitory effect on the growth of the ascites form tumor.

This publication has 25 references indexed in Scilit: